Diffuse alveolar hemorrhage (DAH) is a non-infectious pulmonary complication of bone marrow transplantation (BMT) with resultant high mortality. It reportedly occurs primarily in autologous recipients. We examined the incidence of DAH in our center in order to assess potential risk factors and develop pre- No recognizable alteration in supportive care, conditioning regimen, GVHD prophylaxis or cytokine usage was associated with this striking increase in the frequency of DAH after allografting. Further follow-up is required to establish whether this increase in the incidence of DAH in allogeneic transplantation is an isolated occurrence or an ongoing problem. If indeed there is a real increase in the incidence of this complication, then efforts need to be directed towards elucidating a possible cause or risk factors. We offer the possibility that a new unidentified infection, undetected by current microbiological tests might contribute to this striking increase in DAH. These data, while not establishing a cause, suggest a markedly augmented risk of DAH in allogeneic BMT. In addition, high-dose corticosteroids have only limited efficacy as therapy for DAH after allotransplantation. Further investigation into the pathogenesis of this syndrome is essential as is prompt and immediate consideration of DAH in all patients with respiratory compromise early after BMT. Bone Marrow Transplantation (2000) 26, 539-543.
Pulmonary complications occur in 40% to 60% of patients following bone marrow transplantation (BMT) and are a significant cause of morbidity and mortality. 1 The syndrome of diffuse alveolar hemorrhage (DAH) occurs in 1% to 21% of BMT patients and reportedly occurs more frequently in autologous recipients. [2] [3] [4] [5] This syndrome is characterized by cough, dyspnea and respiratory compromise but hemoptysis is infrequent. The chest X-ray (CXR) shows unilateral or bilateral infiltrates in a predominantly alveolar pattern. 6 The diagnosis is established by bronchoscopy and bronchoalveolar lavage (BAL) which shows a characteristic pattern of increasingly bloodier returns following sequential instillation of saline. 7 In order to examine the incidence, management and outcome of adult BMT patients experiencing this complication we report 7 years experience with this complication at the University of Minnesota Blood and Marrow Transplant Program.
Patients and methods

Patients
Between 1991 and 1997, 922 adult patients received a BMT, including either peripheral blood (PB) or BM stem cells, for hematologic disorders and various malignancies. Data were collected prospectively, coded and stored in the University of Minnesota BMT Biostatistics Database. Review of these records identified 93 patients as having pulmonary hemorrhage. Subsequent review of all available medical records, bronchoscopy reports, microbiologic and virologic data as well as pathologic material confirmed 23 cases fulfilling the clinical and bronchoscopic criteria for DAH (detailed below). The excluded cases included 37 cases of documented infection (candida 11, aspergillus eight, cytomegalovirus (CMV) six, respiratory syncytial virus (RSV) two, other or polymicrobial infection 10). Also excluded were 13 cases of autopsy or lung biopsy diagnosis of DAH without premortem BAL, seven cases of clinical or CXR suggestive diagnoses only without BAL and other causes (13 cases).
Diagnosis
All candidate patients who developed respiratory compromise or a new infiltrate on CXR had fiberoptic bronchoscopy performed. BAL was carried out under standardized conditions with instillation of four aliquots of 20 ml of warm saline. For this report, DAH was diagnosed by strict criteria. DAH was diagnosed if: (1) the returns from lavage became progressively bloodier with each subsequent lavage; and (2) all cytologic, pathologic, microbiologic or virologic studies identified no infection compatible with the diagnosis.
Microbiological techniques
All samples were submitted for cytology plus bacterial, viral and fungal cultures. Cytological examination included KOH, GMS, and Papanicolau stains. Routine Gram stain and bacterial cultures were performed as well as cultures for yeast and filamentous fungi. Viral studies included analysis for CMV, RSV and influenza A antigen, routine viral culture and CMV rapid shell vial culture. CMV DNA analysis was not performed.
Results
Patient characteristics
Clinical characteristics, conditioning and type of transplant of the 23 patients confirmed to have DAH are shown in Table 1 . All the patients had hematologic malignancy; 18 had leukemia, two myelodysplastic syndrome (MDS) and three had lymphoma. Of the patients with leukemia, six The numerator represents the actual number of cases of DAH by category occurring in the years defined.
The denominator is the total number of patients undergoing BMT by category and time.
had high risk disease (CML beyond chronic phase or acute leukemia beyond 1st complete remission). The median patient age was 36 (range 24-62). Of these, 10 were aged 18 to 35, nine were 36 to 49, and 4 were 50 or older. Conditioning was cyclophosphamide (CY) 120 mg/kg and total body irradiation (TBI) 1320 cGy in eight fractions over 4 days in 18 patients. Three patients undergoing a second BMT received busulfan 16 mg/kg over 4 days and CY 200 mg/kg and the remaining two patients received CY/TBI plus etoposide 30 mg/kg. All allogeneic recipients received standard cyclosporine and methotrexate GVHD prophylaxis. Eleven of the 19 allogeneic recipients were CMV IgG antibody positive as were three of the four autologous recipients. Supportive care measures included isolation in HEPA-filtered rooms with positive pressure rapid air exchange; fluid, electrolyte and nutritional support; prophylactic antibiotics, antiviral and antifungal agents; and blood product support as necessary. Antiviral prophylaxis varied depending upon transplant type. Low risk patients, defined as seronegative autologous recipients or allogeneic recipients who were CMV seronegative with CMV-negative donors, received CMV-safe blood products. All CMVseropositive recipients received acyclovir 10 mg/kg three times daily i.v. followed later by 800 mg orally five times daily.
Incidence of diffuse alveolar hemorrhage
The total of 23 cases of DAH out of 922 transplants over a 7 year period represented an actual incidence of 2.5% of all patients receiving BMT. Following autologous transplant four of 426 (0.9%) patients had DAH, 14 of 278 (5.0%) allogeneic related donor (RD) recipients and five of 218 (2.3%) unrelated donor allogeneic (URD) recipients had DAH. The median day of onset of DAH was 19 (range 5-34) days post BMT. Eight cases occurred prior to neutrophil engraftment (absolute neutrophils Ͼ0.5 × 10 9 /l), six cases occurred within 5 days of engraftment and nine cases occurred after engraftment was well established (Figure 1) . In all cases the presenting findings leading to the initial bronchoscopy were respiratory compromise or new infiltrate seen on CXR. In three cases the initial bronchoscopy was negative but repeat bronchoscopy within 2 to 5 days led to the diagnosis. Analysis of lavage fluid showed a leukocyte count of 6 to 1344/l (median 130) and a red cell count of 13 550 to 317 500/l (median 48 375). Microbiological and virological investigations of blood, respiratory secretions and BAL in all patients were negative.
We observed a marked increase in the incidence of DAH during 1997 with 12 of 143 (8.4%) cases seen during this time. There was no seasonal variation with two cases in summer, four cases in winter and three cases each in spring and fall. Of note, seven of 40 (17.5%) cases occurred following allogeneic sibling transplant (Figure 2 ). Of these, four of 22 occurred in recipients of BM stem cells collected by conventional aspiration harvest and three of 18 in recipients of allogeneic G-CSF-mobilized PB stem cells (PBSC). We also noted four of 35 (11.4%) cases in unrelated donor recipients during 1997 which was in contrast to only one case occurring in unrelated donor recipients in the previous 6 years.
We were interested in whether the increased incidence noted during 1997 was a chance deviation or may have represented a continuing change in the frequency of this complication. Our analysis showed a similar increased incidence in the first 6 months of 1998 with five of 67 (7.6%) patients developing DAH. Of these, two of 19 (10.5%) occurred in allogeneic RD recipients, two of five (40%) in URD recipients and one of 42 (2.4%) autologous recipients. Day of onset of DAH Figure 1 Day of onset of diffuse alveolar hemorrhage in relation to absolute neutrophil count at the time DAH was diagnosed by bronchoalveolar lavage.
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Management of DAH and outcome
All patients had aggressive management to maintain optimal fluid and electrolyte balance, hemostatic control including frequent platelet transfusions and correction of any plasma coagulation abnormalities, prophylactic antibiotics as necessary and aggressive ventilatory and oxygen support. High-dose methylprednisolone, 250 mg to 2 g per day was instituted within 1 to 5 days (median 3) of the onset of symptoms or X-ray findings in 15 patients. Mechanical ventilation became necessary in 21 of the 23 patients. Only four of these 21 patients (19%) recovered sufficiently to permit extubation while 17 of the 23 patients (74%) died at a median of 39 days (range 22-47) post transplant; a median of 17 days post onset of DAH (range 5-34). Grade I to II GVHD of the skin developed contemporaneously in five of the 19 allogeneic recipients. Two of these also had GVHD of the gastrointestinal tract while one had severe hepatic GVHD. The attributable causes of death in these patients were multifactorial. The majority of patients experienced multisystem organ failure (n = 11) or subsequent development of sepsis (n = 3, bacterial two, fungal one). Three patients died of primary respiratory failure. Six patients are alive with a median follow-up of 18 months (range 12-60). None of the survivors has residual respiratory compromise.
Discussion
The syndrome of DAH is a poorly understood, non-infectious pulmonary complication occurring after BMT. Previous reports have identified its high mortality. The initial description of this complication reported a 21% incidence in autologous recipients. 2 Risk factors predisposing patients to DAH included age Ͼ40, solid malignancy, onset contemporary with engraftment, fever and severe mucositis. Subsequent studies have shown a lower incidence of DAH occurring following autologous transplant with a reported incidence of 1% to 5%. [3] [4] [5] Recent studies have described a similar incidence in allogeneic recipients with 3% to 7.3% of allogeneic patients developing DAH. 8, 9 In this study we observed an overall incidence of DAH of 2.5% over the last 7 years. Most of these cases occurred following allogeneic transplant. Of particular concern, is the marked increase in cases occurring during 1997 with an overall incidence of 8.4%; 17.5% in allogeneic recipients. Possible spurious causes for this apparent increase in the rate of DAH include more frequent use of bronchoscopy or changes in the interpretation of bronchoscopic findings, yielding an apparent but not real increase in the observed rate. However, no changes in our center's approach to the indications for bronchoscopy or the applied technique of BAL was instituted during this entire interval. In addition, given the severe and life-threatening nature of DAH episodes, it is unlikely that such ascertainment bias is the explanation for the findings. Alternatively, changes in supportive care, changes in utilization of cytokines and the use of PB as a source of stem cells might be postulated as alternative explanations for the observed findings.
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Within our institution bronchoscopy is regularly performed following development of respiratory compromise or any new infiltrate evident on CXR. Bronchoscopy and BAL is performed using a standardized technique with specific protocols for both the lavage volume and specimen processing. Occasional cases might be missed because of the patchy nature of DAH, especially in the early stages of the process. This is illustrated by three of our cases being diagnosed only on the second bronchoscopy.
Careful review identified no clear change in any aspect of supportive care during 1997 that could account for the increased incidence of DAH. Changes that have occurred include the use of hematopoietic-stimulating cytokines, the use of PBSC as a source of stem cells in both autologous and allogeneic recipients, and also the increasing use of unrelated donors. Cytokine support, most notably the use of G-CSF is routinely started on day 1 post transplant for all recipients of PBSC, autologous and allogeneic, and in high risk recipients of allogeneic BM. Of note, the use of allogeneic-related donor PBSC has increased in recent years with our institution performing 18 in 1996 and 22 in 1997. However, the increase in DAH rates observed in 1997 occurred in four allogeneic BM recipients and in three allogeneic PB recipients. As the incidence of DAH was spread across both BM and PBSC recipients, neither the stem cell source nor use of cytokines could account for the increased rate of DAH seen in 1997.
There is a possibility that an infectious agent, not detected by our current microbiological tests, may have contributed to the increased rate of DAH, but we have no evidence to support this hypothesis. We saw no clustering of cases to suggest either a seasonal variation or nosocomial transmission from patient to patient. We perform extensive cytologic and microbiologic analysis of all clinical specimens but these studies may be insensitive to detecting certain pathogens, including filamentous fungi or fastidious microbes like actinomyces or nocardia. However, any patient with progressive pulmonary infiltrates had a second or third bronchoscopy to exclude an infectious cause, thus markedly reducing the likelihood of undiagnosed fungal or bacterial pathogens. Alternatively, an infectious agent that is not detected by current techniques might be present. Human herpesvirus (HHV) 6 has been reported as a frequent cause of pneumonitis although the syndromes attributable to HHV 6 do not include alveolar hemorrhage. [10] [11] Occasional cases of DAH have been ascribed to rare infections such as Mycoplasma hominis. 12 The management of this condition remains frustrating. Despite aggressive measures including the institution of high-dose steroids early in the course of the disease, mortality remains high. Steroids are used because our current understanding of the pathogenesis of this condition suggests that it may represent a non-specific inflammatory response to an undefined initiating insult. Previous studies have shown similar high mortality rates with a substantial number of late deaths occurring due to late acquired fungal infection. In our series, multi-system organ failure was the predominant cause of death and late fungal infections were not seen.
It is of importance to be able to predict which patients are at risk of DAH. We were unable to define any factors that predisposed patients to DAH. Previous studies have defined age Ͼ40, solid malignancy, onset contemporary with engraftment, fever and severe mucositis as predictive factors, 2 but these were not predictive in our study. Our concerns included the use of PBSC as a source of stem cells or the use of cytokines but neither of these factors were associated with more cases of DAH. Improvements in our understanding of the pathogenesis of this condition are vital if new treatment modalities are to be developed for the prevention or treatment of this devastating complication.
